Biren Amin
Stock Analyst at Piper Sandler
(3.34)
# 1,010
Out of 5,030 analysts
62
Total ratings
52.73%
Success rate
2.99%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Biren Amin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LENZ LENZ Therapeutics | Maintains: Overweight | $51 → $67 | $38.51 | +73.98% | 2 | Oct 10, 2025 | |
| OCUL Ocular Therapeutix | Maintains: Overweight | $21 → $31 | $11.61 | +167.13% | 2 | Oct 3, 2025 | |
| MNPR Monopar Therapeutics | Maintains: Overweight | $76 → $95 | $80.14 | +18.54% | 2 | Sep 25, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Neutral | $11 → $15 | $22.10 | -32.13% | 11 | Jul 29, 2025 | |
| BBIO BridgeBio Pharma | Maintains: Overweight | $63 → $68 | $54.91 | +23.84% | 3 | Jul 14, 2025 | |
| ACRS Aclaris Therapeutics | Assumes: Overweight | $6 | $1.92 | +213.32% | 1 | Jul 10, 2025 | |
| CNTX Context Therapeutics | Reiterates: Overweight | $4.5 → $4 | $1.42 | +181.69% | 1 | Jun 26, 2025 | |
| SLDB Solid Biosciences | Maintains: Overweight | $20 → $17 | $5.98 | +184.28% | 2 | May 16, 2025 | |
| ALLO Allogene Therapeutics | Maintains: Overweight | $9 → $7 | $1.23 | +469.11% | 3 | May 14, 2025 | |
| CNTA Centessa Pharmaceuticals | Initiates: Overweight | $38 | $22.93 | +65.72% | 1 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $12 | $4.22 | +184.36% | 1 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $71 | $33.13 | +114.31% | 2 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $19.02 | +84.02% | 1 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $21 | $15.57 | +34.87% | 3 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $91 → $115 | $87.30 | +31.73% | 2 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $40 → $32 | $24.70 | +29.55% | 2 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $7 → $3 | $3.89 | -22.88% | 1 | Jul 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $70 | $1.51 | +4,535.76% | 2 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $51 | $0.84 | +5,972.15% | 1 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $5.30 | +353.26% | 1 | Oct 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $4.65 | +631.18% | 1 | Oct 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $1,050 → $500 | $1.31 | +38,214.18% | 2 | Sep 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $14 | $9.90 | +41.41% | 1 | Jul 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $657 → $691 | $577.75 | +19.60% | 2 | Jun 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $16 → $10 | $3.22 | +210.56% | 1 | Jun 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $101 | $34.17 | +195.58% | 1 | Nov 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $69 | $139.75 | -50.63% | 1 | Oct 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $155 | $418.50 | -62.96% | 5 | Jul 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $136 | $2.50 | +5,340.00% | 4 | Mar 6, 2017 |
LENZ Therapeutics
Oct 10, 2025
Maintains: Overweight
Price Target: $51 → $67
Current: $38.51
Upside: +73.98%
Ocular Therapeutix
Oct 3, 2025
Maintains: Overweight
Price Target: $21 → $31
Current: $11.61
Upside: +167.13%
Monopar Therapeutics
Sep 25, 2025
Maintains: Overweight
Price Target: $76 → $95
Current: $80.14
Upside: +18.54%
Sarepta Therapeutics
Jul 29, 2025
Maintains: Neutral
Price Target: $11 → $15
Current: $22.10
Upside: -32.13%
BridgeBio Pharma
Jul 14, 2025
Maintains: Overweight
Price Target: $63 → $68
Current: $54.91
Upside: +23.84%
Aclaris Therapeutics
Jul 10, 2025
Assumes: Overweight
Price Target: $6
Current: $1.92
Upside: +213.32%
Context Therapeutics
Jun 26, 2025
Reiterates: Overweight
Price Target: $4.5 → $4
Current: $1.42
Upside: +181.69%
Solid Biosciences
May 16, 2025
Maintains: Overweight
Price Target: $20 → $17
Current: $5.98
Upside: +184.28%
Allogene Therapeutics
May 14, 2025
Maintains: Overweight
Price Target: $9 → $7
Current: $1.23
Upside: +469.11%
Centessa Pharmaceuticals
Mar 31, 2025
Initiates: Overweight
Price Target: $38
Current: $22.93
Upside: +65.72%
Feb 19, 2025
Initiates: Overweight
Price Target: $12
Current: $4.22
Upside: +184.36%
Feb 6, 2025
Maintains: Overweight
Price Target: $74 → $71
Current: $33.13
Upside: +114.31%
Dec 2, 2024
Initiates: Overweight
Price Target: $35
Current: $19.02
Upside: +84.02%
Nov 14, 2024
Maintains: Overweight
Price Target: $23 → $21
Current: $15.57
Upside: +34.87%
Nov 8, 2024
Maintains: Overweight
Price Target: $91 → $115
Current: $87.30
Upside: +31.73%
Nov 6, 2024
Maintains: Neutral
Price Target: $40 → $32
Current: $24.70
Upside: +29.55%
Jul 19, 2024
Downgrades: Hold
Price Target: $7 → $3
Current: $3.89
Upside: -22.88%
May 19, 2023
Maintains: Buy
Price Target: $120 → $70
Current: $1.51
Upside: +4,535.76%
Jan 11, 2021
Initiates: Buy
Price Target: $51
Current: $0.84
Upside: +5,972.15%
Oct 30, 2020
Initiates: Buy
Price Target: $24
Current: $5.30
Upside: +353.26%
Oct 19, 2020
Initiates: Buy
Price Target: $34
Current: $4.65
Upside: +631.18%
Sep 14, 2020
Downgrades: Hold
Price Target: $1,050 → $500
Current: $1.31
Upside: +38,214.18%
Jul 24, 2020
Initiates: Buy
Price Target: $14
Current: $9.90
Upside: +41.41%
Jun 12, 2020
Maintains: Buy
Price Target: $657 → $691
Current: $577.75
Upside: +19.60%
Jun 1, 2020
Downgrades: Hold
Price Target: $16 → $10
Current: $3.22
Upside: +210.56%
Nov 9, 2017
Initiates: Buy
Price Target: $101
Current: $34.17
Upside: +195.58%
Oct 3, 2017
Maintains: Buy
Price Target: $66 → $69
Current: $139.75
Upside: -50.63%
Jul 11, 2017
Initiates: Buy
Price Target: $155
Current: $418.50
Upside: -62.96%
Mar 6, 2017
Initiates: Buy
Price Target: $136
Current: $2.50
Upside: +5,340.00%